Argos Therapeutics, Inc. Welcomes Jean Lamarre to Board of Directors
Published: Mar 13, 2013
As president of Lamarre Consultants, Mr. Lamarre brings to the Board more than 15 years of experience in strategic planning and corporate financing for life sciences and information technology companies. In addition to Argos Therapeutics, Mr. Lamarre sits on numerous boards, including Klox Technologies, Mispro Biotech Services inc. and CQVB.
"As a member of Argos Therapeutics' Board of Directors, Jean will provide invaluable expertise in the financial community and the life sciences field, as we continue to enroll in the ADAPT Phase 3 study and advance our other product candidates," said Jeff Abbey, Chief Executive Officer of Argos Therapeutics.
Previously, Mr. Lamarre was Vice President for Canam-Manac Group, one of the largest structural steel companies in North America. While in this role he supervised operations in Mexico, Venezuela, France and China. For 15 years, Mr. Lamarre worked for the Lavalin Group, one of the world's largest engineering and construction firms. He went from managing international projects in Africa and Central America to CFO of the firm for seven years. He was also European Vice President, supervising operations in Belgium, France and England.
Mr. Lamarre holds a Bachelor of Business Administration from HEC Montréal with a specialization in Applied Economics.
In addition to Mr. Lamarre, Argos Therapeutics Board of Directors consists of Hubert Birner, Ph.D., M.B.A. of TVM Capital, Chairman of the Board; Jeffrey D. Abbey, M.B.A., J.D., CEO of Argos Therapeutics; David W. Gryska of Seattle Genetics; Philip R. (Phil) Tracy, J.D. of Intersouth Partners; Brian J. Underdown, B.Sc., Ph.D. of Lumira Capital; and Sander van Deventer, M.D., Ph.D. of Forbion Capital.
About the Arcelis™ Technology Platform
Arcelis is a fully personalized, active immunotherapy technology that captures all antigens, including mutated and variant antigens that are specific to each patient's disease. It has been shown to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that are associated with toxicity. The technology can be leveraged to manufacture personalized therapies for any cancer or infectious disease.
The Arcelis process integrates readily into many current treatment paradigms, using only a small tumor or blood sample and the patient's own dendritic cells, which are derived and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient sample to program the dendritic cells to target the entire disease-antigen repertoire. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered as an intradermal injection to produce the desired patient-specific immune response.
Arcelis technology also overcomes many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. Automated processes allow a single facility to serve all of North America and can be used to treat any cancer or infectious disease with the same manufacturing process and equipment.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos´ most advanced product candidate AGS-003 has initiated a Phase 3 study for the treatment of mRCC, and the Company plans to have data from its Phase 2b study of AGS-004 for the treatment of HIV in late 2013. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
The Ruth Group
Caitlin Cox (media)
Nicole Greenbaum (investors)
Jeff Abbey (partners)